RGNX - Regenxbio Inc
Regenxbio Inc Logo

RGNX - Regenxbio Inc

https://www.regenxbio.com
Hold Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Range-Bound
As of 2025-09-10 (Snapshot)

REGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies intended to affect disease. The company is headquartered in Rockville, Maryland.

52W High
$13.48
52W Low
$5.04
MA Status:
50D: Above 200D: Above
Beta (~1 neutral, <0.9 lower risk)
1.17
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-3.37
EV/Revenue (<3 favorable)
1.57
P/S (TTM) (<3 favorable)
3.15
P/B (<3 favorable)
2.30
Ownership
Institution‑heavy
Source: Overview
Insiders (1–5% typical)
7.65%
Institutions (25–75% balanced)
87.45%
Shares Outstanding
50,514,000
Float
41,403,500
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
155,782,000
Gross Profit (TTM)
128,432,000
EPS (TTM)
-3.44
Profit Margin (>10% good)
-1.13%
Operating Margin (TTM) (higher better)
-2.96%
ROE (TTM) (>15% strong)
-0.63%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
-0.04
Momentum
Bearish momentum
Value
0.3079
Previous
0.3585
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025